MAPT and Alzheimer disease: Our results demonstrate that distinct plasma tau biomarkers can accurately stage AD, offering valuable insights for identifying clinical diagnostic and imaging stages, as well as predicting longitudinal tau-PET accumulation, neurodegeneration and cognitive decline.